Top Page
Petmed Express
(NASDAQ:PETS)
Petmed Express (PETS) vs. SPDR S&P 500 ETF (SPY)
Petmed Express Business Overview & Revenue Model
Petmed Express Earnings Call Summary
Petmed Express Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 247.01M | 226.97M | 281.06M | 256.86M | 273.42M | 303.58M |
| Gross Profit | 66.65M | 69.14M | 78.65M | 71.01M | 76.94M | 84.32M |
| EBITDA | 7.51M | 6.71M | -1.11M | 10.99M | 27.03M | 32.96M |
| Net Income | 357.00K | -6.27M | -7.46M | 5.14M | 18.72M | 23.92M |
Balance Sheet | ||||||
| Total Assets | 144.79M | 148.70M | 169.88M | 167.48M | 176.32M | 187.50M |
| Cash, Cash Equivalents and Short-Term Investments | 50.10M | 54.72M | 55.30M | 104.09M | 111.08M | 118.72M |
| Total Debt | 1.10M | 996.00K | 1.45M | 995.00K | 0.00 | 0.00 |
| Total Liabilities | 48.61M | 63.57M | 73.15M | 57.51M | 34.13M | 46.22M |
| Stockholders Equity | 96.18M | 85.13M | 96.73M | 123.80M | 142.19M | 141.28M |
Cash Flow | ||||||
| Free Cash Flow | 856.00K | -395.00K | -194.00K | 22.54M | 16.75M | 37.64M |
| Operating Cash Flow | 4.83M | 4.72M | 4.32M | 27.80M | 18.50M | 40.08M |
| Investing Cash Flow | -3.98M | -5.11M | -40.67M | -10.26M | -1.75M | -2.43M |
| Financing Cash Flow | -194.00K | -181.00K | -12.44M | -24.54M | -24.38M | -22.69M |
Petmed Express Technical Analysis
Petmed Express Risk Analysis
Petmed Express Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $52.96M | ― | ― | ― | -19.25% | 14.47% | |
| ― | $275.02M | ― | ― | ― | 37.74% | 69.79% | |
| ― | $117.84M | -0.99 | -130.27% | ― | ― | 35.81% | |
| ― | $82.95M | ― | -63.41% | ― | -87.59% | 11.53% | |
| ― | $37.95M | -3.69 | ― | ― | -3.54% | 77.98% |
Petmed Express Corporate Events
On October 19, 2025, PetMed Express appointed James LaCamp as a director and Audit Committee Chair, effective immediately. LaCamp, with nearly two decades of experience in finance and accounting, is expected to enhance the company’s financial governance and oversight. Additionally, on October 20, 2025, the company entered into an Interim Executive Employment Agreement with Leslie C.G. Campbell, who will serve as Interim CEO and President for a year, highlighting the company’s strategic focus on board composition and leadership to drive growth and shareholder value.
The most recent analyst rating on (PETS) stock is a Sell with a $3.00 price target. To see the full list of analyst forecasts on Petmed Express stock, see the PETS Stock Forecast page.
On October 1, 2025, PetMed Express announced a $1.2 million non-cash impairment of its PCRX trade name for the quarter ended March 31, 2025, due to reduced actual and forecasted revenues. This impairment does not require future cash expenditures but highlights potential financial challenges, as the company also faces a sustained decline in its stock price, which may indicate further goodwill impairments affecting its financial condition and capital access.
The most recent analyst rating on (PETS) stock is a Sell with a $3.00 price target. To see the full list of analyst forecasts on Petmed Express stock, see the PETS Stock Forecast page.
On September 8, 2025, PetMed Express, Inc.’s Board of Directors approved an initial annual base salary of $550,000 for Leslie C.G. Campbell, who began her role as Interim CEO and President on August 11, 2025. Additionally, the Board granted a restricted stock award of 10,000 shares to Douglas Krulik, the Chief Accounting Officer and Interim Principal Financial Officer, under the company’s 2024 Omnibus Incentive Plan, with the award vesting six months after the grant date.
The most recent analyst rating on (PETS) stock is a Sell with a $3.00 price target. To see the full list of analyst forecasts on Petmed Express stock, see the PETS Stock Forecast page.
On August 20, 2025, PetMed Express received a notice from Nasdaq due to a delay in filing its Annual and Quarterly Reports, leading to non-compliance with Nasdaq’s listing rules. The company has until September 1, 2025, to submit a compliance plan, and if accepted, it could have until December 29, 2025, to regain compliance. The notice does not immediately affect the company’s stock listing, and PetMed Express is working diligently to file the reports promptly.
The most recent analyst rating on (PETS) stock is a Sell with a $3.00 price target. To see the full list of analyst forecasts on Petmed Express stock, see the PETS Stock Forecast page.
On August 11, 2025, PetMed Express, Inc. announced significant management changes with the resignation of CEO Sandra Campos and CFO Robyn D’Elia, both of whom entered into separation agreements to provide consulting services for three months. Leslie C.G. Campbell has been appointed as Interim CEO, and Doug Krulik as Interim CFO, as the company initiates a search for permanent replacements. These changes come amid an ongoing investigation by the Audit Committee into revenue recognition and other operational issues, potentially impacting company performance and stakeholder confidence.
The most recent analyst rating on (PETS) stock is a Sell with a $3.50 price target. To see the full list of analyst forecasts on Petmed Express stock, see the PETS Stock Forecast page.
PetMed Express, Inc. has announced a delay in filing its Form 10-Q (Quarter Report) for the period ending June 30, 2025. The delay is primarily due to the need for additional time for the Audit Committee to complete an ongoing investigation, which is crucial for finalizing the company’s Form 10-K (Yearly Report) for the fiscal year ended March 31, 2025. The company anticipates filing the delayed reports as soon as the investigation is complete, although no specific timeline has been provided. PetMed Express has indicated that significant changes in financial results are expected, but a reasonable estimate cannot be made at this time due to the ongoing investigation. The company is committed to resolving these issues promptly and ensuring compliance, as evidenced by the signature of Robert Lawsky, General Counsel, on the notification.
The most recent analyst rating on (PETS) stock is a Sell with a $3.50 price target. To see the full list of analyst forecasts on Petmed Express stock, see the PETS Stock Forecast page.
On July 24, 2025, Diana Garvis Purcel resigned from the board of directors of PetMed Express, Inc., including her roles as Chair of the Audit Committee and a member of the Audit and Compensation and Human Capital Committees. Her resignation was not due to any disagreements with the company. Following her departure, Leslie C.G. Campbell was appointed to serve on the Audit Committee and as its Chair. The board also decided to reduce its size from seven to six directors.
The most recent analyst rating on (PETS) stock is a Sell with a $3.50 price target. To see the full list of analyst forecasts on Petmed Express stock, see the PETS Stock Forecast page.